Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
Date:3/5/2012

SAN DIEGO, March 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2011 financial results on Monday, March 12, 2012.

Cadence management will host a conference call and live webcast to discuss the financial results on Monday, March 12, 2012 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  For more information about Cadence, please visit www.cadencepharm.com.

 Contacts:

William R. LaRue 

SVP & Chief Financial Officer 

Cadence Pharmaceuticals, Inc. 

858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
7. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Summit for ... to support the development of a patient-specific stem cell therapy for the treatment of ... lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, CA. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... support for Connecticut's innovative, growing companies, today announced the launch of VentureClash ... technology (fintech) companies. , “VentureClash looks to attract the best early-stage ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments ... heavy metals, and more. Expo attendees can stop by booth 1021 to learn ...
(Date:4/27/2016)... British Virgin Islands (PRWEB) , ... April 27, ... ... Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton ... he was an Executive Director and one of the founding commercial leaders responsible ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):